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Abstract: The three-phase response of urinary serotonin and dopamine in subjects 
  simultaneously taking amino acid precursors of serotonin and dopamine has been defined.1,2 
No model exists regarding the renal etiology of the three-phase response. This writing outlines 
a model explaining the origin of the three-phase response of urinary serotonin and dopamine. 
A “dual-gate lumen transporter model” for the basolateral monoamine transporters of the kidneys 
is proposed as being the etiology of the three-phase urinary serotonin and dopamine responses.
Purpose: The purpose of this writing is to document the internal renal function model that 
has evolved in research during large-scale assay with phase interpretation of urinary serotonin 
and dopamine.
Patients and methods: In excess of 75,000 urinary monoamine assays from more than 
7,500 patients were analyzed. The serotonin and the dopamine phase were determined for 
specimens submitted in the competitive inhibition state. The phase determination findings were 
then correlated with peer-reviewed literature.
Results: The correlation between the three-phase response of urinary serotonin and dopamine 
with internal renal processes of the bilateral monoamine transporter and the apical monoamine 
transporter of the proximal convoluted renal tubule cells is defined.
Conclusion: The phase of urinary serotonin and dopamine is dependent on the status of the 
serotonin gate, dopamine gate, and lumen of the basolateral monoamine transporter while in 
the competitive inhibition state.
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Introduction
The first step in development of the model was validation of peer-reviewed literature. 
Scientific knowledge of the monoamines (serotonin, dopamine, norepinephrine, and 
epinephrine) has grown significantly since 1990. Along with this growth in knowledge, 
some of the science originally thought to be correct has been discredited. In contrast 
to earlier writings it is now known that monoamines do not cross the blood-brain 
barrier. Monoamines are not simply filtered at the glomerulous then excreted into the 
urine. Urinary monoamine levels are not a direct assay of the peripheral or central 
nervous system monoamine levels. Interpretation of urinary monoamine assays is more 
complex than simply determining if urinary serotonin and dopamine levels found on 
assay are high or low. Under normal conditions, significant amounts of serotonin and 
dopamine filtered at the glomerulous do not make it to the final urine. Serotonin and 
dopamine (herein referred to as “monoamines”) found in the final urine are newly 
synthesized in the kidneys.1,2Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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The monoamines and their amino acid precursors are 
filtered at the glomerulous then enter the proximal tubules 
of the kidneys. They are transported by organic cation 
transporters out of the proximal tubules into the proximal 
convoluted renal tubule cells. The monoamines filtered at 
the glomerulous are metabolized in the proximal convoluted 
renal tubule cells. Very little of these monoamines filtered 
at the glomerulous are found in the final urine of normal 
subjects. Monoamine amino acid precursors filtered at the 
glomerulous are synthesized in the proximal convoluted renal 
tubule cells into new monoamines, which are then detected 
in the final urine.2
Serotonin and dopamine exist in two states: the “endogenous 
state” found when no additional amino acid precursors are 
being administered, and the “competitive inhibition state” 
found when the amino acid precursors of both serotonin and 
dopamine are being administered.3
Prior to discussing the dual-gate lumen model, the fol-
lowing discussion of the three-phase urinary response is put 
forth based on previous peer reviewed literature.2
Literature notes: “Urinary monoamine neurotransmitter 
testing prior to initiation of serotonin and dopamine amino 
acid precursors is of no value. There is no correlation between 
baseline testing and urinary neurotransmitter phases once the 
patient is taking amino acid precursors. It is not necessary 
or even useful to measure baseline urinary neurotransmitters 
in treatment”.2,4
Urinary monoamine neurotransmitters are neurotrans-
mitters that are synthesized by the kidneys and excreted 
into the urine or secreted into the system via the renal 
veins.1,2,5 With simultaneous administration of serotonin and 
dopamine amino acid precursors, three phases of urinary 
neurotransmitter response have been identified on labora-
tory assay of the urine (Figures 1 and 2). The three phases 
of response apply to both serotonin and dopamine. In all 
the life forms tested that have kidneys along with serotonin 
and catecholamine systems, the three phases of urinary 
neurotransmitter response exist.40 In reviewing the literature, 
it would appear that the three phases of urinary response 
to neurotransmitters were present in previous writings but 
were not identified as such. For example, a 1999 article 
notes that administration of L-dopa can increase urinary 
dopamine levels (phase 3) and decrease urinary serotonin 
levels (phase 1).2,6
To determine the phase of serotonin and dopamine with 
certainty requires two urinary monoamine neurotransmitter 
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Figure 1 The three phases of urinary neurotransmitter excretion in response to amino acid dosing. The horizontal axis is not labeled with specific amounts; it reflects 
the general trend seen in the population. Amino acid dosing needs are highly individualized. The dosing level needed to inflect into the next level varies greatly throughout 
the general population. For example, some patients inflect into phase 3 on 37.5 mg of 5-HTP per day, while others need as high as 3,000 mg per day (source: DBS   
Labs database).Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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assays to be performed with the subject simultaneously 
taking a different amino acid dosing of dopamine and/or 
serotonin amino acid precursors on each test and comparing 
the results.1,2
In phase 1, monoamine neurotransmitters synthesized 
by the kidneys are excreted into the urine instead of being 
secreted into the system via the renal vein where they 
are needed (Figures 1 and 2). Increasing the amino acid 
dose in phase 1 will correct the problem of urinary monoam-
ine excretion into the urine at the expense of secretion into 
the system. The amino acid precursor dosing of serotonin and 
dopamine, where the individual patient is in phase 1 varies 
widely in the population. The level at which the urinary sero-
tonin is no longer in phase 1 ranges from 37.5 mg of 5-HTP 
per day to 3,000 mg of 5-HTP per day. The level at which 
the urinary dopamine is no longer in phase 1 ranges from no 
L-dopa (with the use of L-tyrosine only in some subjects) to 
540 mg of L-dopa per day in the subjects not under treatment 
for Parkinsonism or Restless Leg Syndrome.1,2
By increasing the amino acid dosing of serotonin and 
dopamine precursors above the dosing of phase 1, the phase 
2 response is observed (Figures 1 and 2). In phase 2, urinary 
monoamine levels are low (,475 micrograms dopamine 
per gram of creatinine or ,80 micrograms serotonin per 
gram of creatinine, the neurotransmitter – creatinine ratio 
compensates for dilution of the urine), and the inappropri-
ate excretion of neurotransmitters into the urine has ceased. 
When in phase 2, serotonin and/or dopamine is being pri-
marily secreted into the system and not excreted into the 
urine. The model used to explain phase 2 is, “inappropriate 
excretion of neurotransmitters has now ceased as the amino 
acid precursor dosing is increased and systemic levels are 
not increasing appropriately.”1,2
As serotonin and dopamine amino acid precursors are 
increased above the phase 1 and the phase 2 levels, all sub-
jects enter the phase 3 response (Figures 1 and 2). Further 
increases in the amino acid dosing lead to increases in urinary 
dopamine and serotonin neurotransmitter levels if they are 
in phase 3. Phase 3 represents appropriate secretion into the 
system and appropriate excretion of excess neurotransmitters 
synthesized by the kidneys into the urine.1,2
Material and methods
Prior to this writing there has been no peer-reviewed pub-
lication setting forth an internal renal model to explain the 
etiology of the three-phase response of urinary serotonin 
and dopamine. This model is based on analysis of in excess 
of 75,000 monoamine assays (serotonin, dopamine, norepi-
nephrine, and epinephrine) from more than 7,500 human 
subjects with samples obtained either in the endogenous state 
or the competitive inhibition state under conditions covered 
in previous writings on the three-phase response.1,2 The uri-
nary phase of serotonin and dopamine was determined for 
assay samples obtained in the competitive inhibition state. 
Knowledge gained through large-scale phase interpretation 
in correlation with peer-reviewed renal literature is the basis 
for the model.
Urine samples were collected 6 hours prior to bedtime 
with 4:00 PM being the most frequent collection time point. 
The samples were obtained in 6 N HCl to preserve dopamine 
and serotonin. The urine samples were collected after a 
minimum of one week at a specific dose of the precursor 
being consumed. Samples were shipped to DBS Laboratories 
(Duluth, MN, USA) under the direction of one of the authors 
(Dr T Uncini, hospital-based dual board certified laboratory 
pathologist). Urinary dopamine and serotonin were assayed 
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Figure 2 The three phases of urinary response to amino acid dosing (Two urinary neurotransmitter tests are required to determine the phase with certainty). PHASE 1: In 
phase 1, as the amino acid dosing increases or decreases the urinary serotonin or dopamine decreases or increases respectively. in phase 1, there is inappropriate excretion 
of neurotransmitters into the urine instead of the system where they are needed. PHAse 2: in phase 2, as the amino acid dosing increases or decreases the urinary serotonin 
or dopamine is low (,80 µg/g creatinine for serotonin or ,300 µg/g creatinine for dopamine). in phase 2, there is no inappropriate excretion of neurotransmitters into the 
urine. The neurotransmitters are being excreted appropriately into the system and the urine. PHAse 3: in phase 3, as the amino acid dosing increases or decreases the urinary 
serotonin or dopamine increases or decreases respectively. In phase 3, there are adequate systemic serotonin and dopamine levels. The excess serotonin and dopamine are 
appropriately excreted into the urine.Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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utilizing commercially available radioimmunoassay kits 
(3 CAT RIA IB88501 and IB89527, both from Immuno 
Biological Laboratories, Inc., Minneapolis, MN, USA). The 
DBS laboratory is accredited as a high complexity laboratory 
by CLIA to perform these assays.
Results
When in the three-phase response, the two systems become 
completely intertwined to the point that changes in one sys-
tem will affect not just that system but the other system as 
well.2 With administration of the dopamine precursor L-dopa 
and the serotonin precursor 5-HTP there is no biochemical 
feedback regulation in the synthesis of dopamine and/or sero-
tonin, respectively. There is a direct proportion between the 
amount of L-dopa and 5-HTP administered and the amount 
of dopamine and serotonin synthesized.1,2
The three-phase response occurs only in the competitive 
inhibition state. It is the response of the newly synthesized 
renal serotonin and dopamine found in the urine to the 
manipulation of serotonin and/or dopamine amino acid 
precursor dosing. With each simultaneous urinary assay of 
serotonin and dopamine in the competitive inhibition state, 
a three-phase model for serotonin and dopamine must be 
independently conceptualized. Serotonin and dopamine may 
be in any one of the three phases simultaneously, with one 
exception. Urinary serotonin and dopamine are never found 
in phase 1 simultaneously.1,2
In Figure 1, increasing or decreasing one or both amino 
acid precursors of serotonin or dopamine in the competitive 
inhibition state allows for determination of the urinary phase 
of both serotonin and dopamine.1,2
The following renal model is the basis for conceptualiza-
tion of the dual-gate lumen model. While numerous transport 
and cell wall crossing mechanisms exit in the proximal con-
voluted renal tubule cells, primary transport out of the proxi-
mal convoluted renal tubule cells for the newly synthesized 
serotonin and dopamine is via the organic cation transporters 
(OCT). Newly synthesized serotonin and dopamine exit the 
proximal convoluted renal tubule cells primarily by one of 
two routes. They are either transported across the basolateral 
membrane via the basolateral transporter (an OCT trans-
porter) or transported across the apical membrane via the 
apical transporter (an OCT transporter).7,8 For the purpose of 
this model, the basolateral membrane transporter (OCT) is 
deemed as being dominant. Newly synthesized serotonin and 
dopamine, not transported across the dominant basolateral 
membrane, are transported out of the proximal convoluted 
renal tubule cells by the apical transporters and detected 
in the final urine as waste. In reviewing urinary assays of 
serotonin and dopamine in the competitive inhibition state, 
the interpreter is viewing monoamines not transported by 
the basolateral monoamine transporters (organic cation 
transporters). While numerous other renal functions and 
interactions have been described, these forces are viewed 
as minor to insignificant in comparison to the dominating 
force of the basolateral and apical transport on the newly 
synthesized monoamines.
Discussion
Models of organic cation transporters of serotonin and dop-
amine have been defined in the past. One such model was 
the “gate-lumen-gate model”.9–13 The gate-lumen-gate model 
and other models do not explain the phenomenon observed 
under the three-phase urinary response when both serotonin 
and dopamine are in the competitive inhibition state.
It is purposed that the basolateral monoamine trans-
porter is a “dual-gate lumen transporter” (Figure 3). The 
transporter has a serotonin gate and a dopamine gate at 
the transporter entrance, which function independently of 
each other.
Primary forces affecting transport through the basolateral 
monoamine transporter and the apical monoamine transporter 
are the status of the basolateral monoamine transporter sero-
tonin and dopamine gates, and lumen saturation. The serotonin 
and dopamine gates at the entrance of the basolateral mono-
amine transporters can be either partially closed (impeding 
transporter lumen access by the monoamines) or open (with 
no impedance). The status of the basolateral monoamine 
transporter lumen is either saturated or not saturated.
Correlations of the three-phase model and dual-gate lumen 
model considerations are as follows. In phase 1 the monoam-
ine gate is partially closed impeding access to the transporter 
lumen. In phase 2 and phase 3 the monoamine gate is open 
giving full access of the monoamine to the transporter lumen. 
In phase 1 and phase 2 basolateral monoamine transport 
through the lumen is not saturated. In phase 3 the basolateral 
monoamine transport through the lumen is saturated. Open-
ing and closing of a gate is not solely dependent on changes 
in associated monoamine levels. The opening and closing of 
the gates is dependent on the total amount of serotonin and 
dopamine presenting at the transporter.
 In the competitive inhibition state, a serotonin gate or a 
dopamine gate in phase 1 (partially closed) can be opened 
or closed by adding or subtracting the total amount of amino 
acid precursors administered. This causes an increase or 
decrease in the total amount of serotonin and dopamine Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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presenting at the transporter. As the gate opens, more 
  monoamine has access to the transporter and is transported, 
causing a drop in the amount of monoamine transported by 
the apical transporter and found in the final urine.
In phase 2 the gate is open with full access to the trans-
porter by monoamine. The transporter effectively transports 
most of the monoamine through the lumen leading to a very 
small amount of monoamine being transported by the apical 
transporter and found in the final urine.
In phase 3 the gate is open and the transporter is saturated. 
Increases or decreases in the total amount of the monoam-
ine presenting at the transporter will lead to an increase or 
decrease in the amount of monoamine found in the final urine. 
When both serotonin and dopamine are in phase 3, increasing 
the amino acid precursor dosing of one monoamine will cause 
increased transport of the associated monoamine at both 
the basolateral and apical transporters. Due to competitive 
inhibition, transport of the other monoamine will decrease 
at the basolateral transporter and increase at the apical trans-
porter. Administration of one amino acid precursor with both 
  serotonin and dopamine in phase 3 leads to an increase in 
apical transport of both monoamines with associated increase 
of urinary levels of both on assay.
Conclusion
Assay of the urinary monoamines, serotonin and dopamine, 
in the competitive inhibition state is an assay of the newly 
synthesized serotonin and dopamine of the kidneys not 
transported by the basolateral monoamine transport. The 
two primary forces affecting transport across the basolateral 
membrane and responsible for the three-phase response are 
the status of the basolateral monoamine transporter gates 
and the saturation of the lumen. Proper assay interpretation 
in the competitive inhibition state is a determination of 
the states of serotonin and dopamine phases relative to the 
basolateral monoamine transporter status. It is not the intent 
of this writing to explore all known aspects of the basolat-
eral monoamine transporter, apical monoamine transporter 
properties, or renal properties in the context of the three-
phase response. The model presented here is intended to 
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Figure 3 The dual-gate lumen model. The basolateral monoamine transporters contain three key components: a serotonin gate, a dopamine gate, and a lumen.Neuropsychiatric Disease and Treatment
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be used as a foundation and reference point for continuing 
discussion, further studies, refinement of the model, and 
future investigation of renal and urinary serotonin and 
dopamine response to amino acid manipulation in the 
competitive inhibition state.
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